Haisco Pharmaceutical Group Co. Ltd. - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Nuvectis Pharma’s licensing deal with Haisco Pharmaceutical expands its clinical-stage pipeline into complement Factor B inhibition and BRAF-mutated cancer therapy, while investors weigh the funding challenge behind the $1.421 billion milestone opportunity. Representative image.

Read More

Pharma Industry News

Nuvectis (NVCT) licenses two Haisco drugs as $1.46bn deal transforms its pipeline

Nuvectis licenses two Haisco drugs in a deal worth up to $1.46 billion. Find out how financing risk could reshape NVCT’s pipeline and investor outlook next.

June 22, 2026

web analytics